Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
How Much Was The Buccal Drug Delivery System Market Worth In 2025, And What Is Its Anticipated Value By 2029?
The market encompassing buccal drug delivery systems has experienced robust expansion recently, projected to escalate from a valuation of $3.55 billion in the year 2024 to $3.89 billion by 2025, reflecting a compound annual growth rate of 9.5%. This upswing observed during the historical span is underpinned by factors such as the emergence of pioneering drug delivery technologies, increasing acceptance within the pharmaceutical sector, demonstrated clinical success and effectiveness, the implementation of targeted market entry approaches, and specialized uses tailored to particular ailments.
The projected trajectory for the buccal drug delivery system market indicates substantial expansion in the coming years, with its valuation anticipated to reach $5.88 billion by 2029, fueled by a compound annual growth rate (CAGR) of 10.9%; this surge during the projection timeframe stems from factors such as an increasing focus on patient-centered administration methods, the growing proportion of elderly individuals, the escalating need for precision therapies, the delivery of biologics and peptides, supportive regulatory frameworks and clearances, alongside considerable investment in research and development initiatives, while prominent developments anticipated to shape this era encompass heightened emphasis on patient ease of use and adherence, ongoing innovations in medicinal preparations, the increasing prevalence of long-term health conditions, specialized attention to pediatric and elderly populations, and improved absorption rates of active ingredients.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8290&type=smp
What Are The Top Growth Drivers Impacting The Buccal Drug Delivery System Market Outlook?
The increasing incidence of long-term health conditions is projected to fuel the expansion within the buccal drug delivery systems market in the near future. Chronic ailments, defined as conditions spanning a year or more, encompass numerous persistent health issues like diabetes, heart conditions, stroke, and various forms of cancer, alongside arthritis; these widespread illnesses demand ongoing medical attention and nutritional management as they are typically manageable rather than curable. Buccal delivery mechanisms offer a suitable and efficacious route for administering medications intended for mucosal and transmucosal absorption, a necessity for numerous individuals afflicted with chronic diseases such as cancer and diabetes. To illustrate the scale, the World Health Organization, a United Nations agency based in Switzerland, reported in September 2023 that chronic diseases, or non-communicable diseases (NCDs), were responsible for 41 million fatalities annually worldwide, accounting for three-quarters of all deaths; specifically, cardiovascular ailments caused 17.9 million deaths, cancers resulted in 9.3 million deaths, chronic respiratory conditions led to 4.1 million deaths, and diabetes was the cause of 2.0 million deaths. Consequently, the escalating rate of chronic disease occurrence serves as a significant catalyst for the growth trajectory of the buccal drug delivery systems market.
What Are The Major Segment Types Covered In The Buccal Drug Delivery System Market?
The buccal drug delivery systemmarket covered in this report is segmented –
1) By Type: Sublingual, Buccal Tablets And Lozenges, Oral Sprays
2) By Application: Pain Management, Smoking Cessation, Angina Pectoris
3) By End-User: Hospitals, Ambulatory Centers, Other End-Users
Subsegments:
1) By Sublingual: Sublingual Tablets, Sublingual Films
2) By Buccal Tablets And Lozenges: Buccal Tablets, Buccal Lozenges
3) By Oral Sprays: Spray Solutions, Spray Gels
Which Market Trends Are Creating New Opportunities In The Buccal Drug Delivery System Industry?
Leading enterprises within the buccal drug delivery systems sector are concentrating their efforts on engineering novel therapeutic avenues, notably oral modalities for managing plaque psoriasis, with the goal of elevating patient health results and boosting the performance of drug administration. The concept of an oral treatment for plaque psoriasis involves medicaments ingested orally designed to control and reduce the manifestations of this persistent autoimmune disorder, which involves accelerated skin cell proliferation resulting in the formation of dense, crimson, scaly areas. To illustrate this progress, the US pharmaceutical giant, Bristol Myers Squibb, secured authorization from the FDA in September 2022 for Sotyktu (deucravacitinib), an ingestible medication intended for adults afflicted with plaque psoriasis of moderate to severe intensity. This governmental clearance signifies the introduction of the first innovative systemic drug for this ailment in roughly ten years, presenting a distinct therapeutic pathway as a selective inhibitor targeting tyrosine kinase 2 (TYK2).
Which Leading Companies Dominate The Buccal Drug Delivery System Market Share?
Major companies operating in the buccal drug delivery system market are Teva Pharmaceuticals Industries Ltd., Pfizer Incorporated, GlaxoSmithKline Public Limited Company, Indivior PLC, Generex Biotechnology Corporation, Catalent Inc., Arx Limited Liability Company, BioDelivery Science International Incorporated, Cynapsus Therapeutics Incorporated, Endo Pharmaceuticals Public Limited Company, Medlab Clinical Ltd., AstraZeneca PLC, F Hoffmann-La Roche Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Novartis AG, Novo Nordisk A/S, Ethypharm SAS, Applied Pharma Research SA, Sunovion Pharmaceuticals Inc., Sanofi SA, Bayer AG, Adare Pharmaceuticals Inc., NAPP Pharmaceutical Ltd., Perrigo Company PLC, Reckitt Benckiser Group PLC, Teligent Pharma Inc., Par Pharmaceutical Companies Inc., Acorda Therapeutics Inc., Opiant Pharmaceuticals Inc.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/buccal-drug-delivery-system-global-market-report
Which Regional Markets Are Contributing Most To The Buccal Drug Delivery System Industry Expansion?
North America was the largest region in the buccal drug delivery systems market share in 2024. The regions covered in the buccal drug delivery system market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Buccal Drug Delivery System Market Report:
https://www.thebusinessresearchcompany.com/customise?id=8290&type=smp
Browse Through More Reports Similar to the Global Buccal Drug Delivery System Market 2025, By The Business Research Company
Drug Delivery Devices Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/drug-delivery-devices-global-market-report
Implantable Drug Delivery Devices Global Market Report 2025
Injectable Drug Delivery Devices Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model